Publications by authors named "Mauricio Cuello Fredes"

Objective: To revise FIGO staging of carcinoma of the cervix uteri, allowing incorporation of imaging and/or pathological findings, and clinical assessment of tumor size and disease extent.

Methods: Review of literature and consensus view of the FIGO Gynecologic Oncology Committee and related societies and organizations.

Results: In stage I, revision of the definition of microinvasion and lesion size as follows.

View Article and Find Full Text PDF

The gene Oct4 encodes a transcription factor critical for the maintenance of pluripotency and self-renewal in embryonic stem cells. In addition, improper re-activation of Oct4 contributes to oncogenic processes. Herein, we describe a novel designer zinc finger protein (ZFP) capable of upregulating the endogenous Oct4 promoter in a panel of breast and ovarian cell lines carrying a silenced gene.

View Article and Find Full Text PDF
Article Synopsis
  • Ovarian cancer is a major health threat, often diagnosed late when it spreads throughout the abdomen, highlighting the need for new treatment strategies.
  • Researchers developed an artificial transcription factor (ATF) to enhance the expression of Maspin, a protein that helps suppress metastasis, in aggressive ovarian cancer cell lines.
  • The study showed that using ATFs could effectively inhibit tumor growth and invasion in lab models, with promising implications for targeted therapies in advanced ovarian cancer.
View Article and Find Full Text PDF

Synopsis of recent research by authors named "Mauricio Cuello Fredes"

  • - Mauricio Cuello Fredes has contributed to gynecologic oncology, particularly focusing on the revised FIGO staging for cervical carcinoma, which incorporates imaging and clinical assessments to better define tumor size and disease extent.
  • - His research also explores genetic mechanisms in cancer, notably through the activation of the Oct4 gene associated with pluripotency using designer zinc finger transcription factors, emphasizing its implications in breast and ovarian cancer.
  • - A significant aspect of his work targets therapeutic advancements in serous epithelial ovarian cancer, addressing the critical need for effective treatments in advanced disease stages characterized by peritoneal carcinomatosis.*